These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17607535)

  • 1. Drug-eluting stents, restenosis and revascularization.
    Ramcharitar S; Gaster AL; Daemen J; Serruys P
    Herz; 2007 Jun; 32(4):287-95. PubMed ID: 17607535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular pathology of drug-eluting stents.
    Nakazawa G; Finn AV; Virmani R
    Herz; 2007 Jun; 32(4):274-80. PubMed ID: 17607533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angioscopic findings after drug-eluting stent implantation.
    Takano M; Mizuno K
    Herz; 2007 Jun; 32(4):281-6. PubMed ID: 17607534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-eluting stents: from evidence to policy.
    Marchetti M
    Expert Rev Med Devices; 2004 Sep; 1(1):49-63. PubMed ID: 16293010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory issues facing the development of drug-eluting stents: a US FDA perspective.
    Boam AB
    Expert Rev Med Devices; 2006 May; 3(3):297-300. PubMed ID: 16681451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Degradable, drug-eluting stents: a new frontier for the treatment of coronary artery disease.
    Kohn J; Zeltinger J
    Expert Rev Med Devices; 2005 Nov; 2(6):667-71. PubMed ID: 16293093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmable elution profile coating for drug eluting stents.
    Al-Lamee K
    Med Device Technol; 2005 Mar; 16(2):12-5. PubMed ID: 15828493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug-eluting stents for diabetic patients. A critical appraisal of the currently available data from randomized trials].
    Silber S; Herdeg C
    Herz; 2008 Apr; 33(3):196-205. PubMed ID: 18568314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local perivascular delivery of anti-restenotic agents from a drug-eluting poly(epsilon-caprolactone) stent cuff.
    Pires NM; van der Hoeven BL; de Vries MR; Havekes LM; van Vlijmen BJ; Hennink WE; Quax PH; Jukema JW
    Biomaterials; 2005 Sep; 26(26):5386-94. PubMed ID: 15814137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Stent thrombosis in the era of drug-eluting stents].
    Wöhrle J
    Herz; 2007 Aug; 32(5):411-8. PubMed ID: 17687531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts.
    Gioia G; Benassi A; Mohendra R; Chowdhury K; Masood I; Matthai W
    Catheter Cardiovasc Interv; 2008 Jul; 72(1):13-20. PubMed ID: 18561143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study.
    Ellis SG; Kandzari D; Kereiakes DJ; Pichard A; Huber K; Resnic F; Yakubov S; Callahan K; Borgman M; Cohen SA
    J Invasive Cardiol; 2007 Oct; 19(10):404-9. PubMed ID: 17906340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of the TAXUS Liberté SR paclitaxel-eluting coronary stent.
    Ahmed WH
    Expert Rev Med Devices; 2007 Mar; 4(2):117-20. PubMed ID: 17359218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.
    Schömig A; Dibra A; Windecker S; Mehilli J; Suárez de Lezo J; Kaiser C; Park SJ; Goy JJ; Lee JH; Di Lorenzo E; Wu J; Jüni P; Pfisterer ME; Meier B; Kastrati A
    J Am Coll Cardiol; 2007 Oct; 50(14):1373-80. PubMed ID: 17903638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological effects of drug-eluting stents in the coronary circulation.
    Steffel J; Tanner FC
    Herz; 2007 Jun; 32(4):268-73. PubMed ID: 17607532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of drug-eluting stents in the coronary artery in ST-elevation myocardial infarction at a single high-volume medical center.
    Bose R; Gupta G; Grayburn PA; Laible EA; Kang MJ; Choi JW
    Am J Cardiol; 2007 Sep; 100(6):949-52. PubMed ID: 17826375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of the tacrolimus drug-eluting Janus stent: a prospective two-centre registry in high-risk patients.
    Romagnoli E; Leone AM; Burzotta F; Trani C; Angeloni G; Materazzo G; Niccoli G; De Vita M; Perfetti M; Mazzari MA; Mongiardo R; Rebuzzi AG; Schiavoni G; Crea F
    J Cardiovasc Med (Hagerstown); 2008 Jun; 9(6):589-94. PubMed ID: 18475127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.